[Effect of adjuvant infusion therapy of low molecular weight dextrans (Infukoll M 40) and deproteinized hemoderivate (Actovegin) in Fontaine stage IV chronic arterial occlusive diseases].
A selected group of 18 patients (among them 16 diabetics) with chronic disorders of arterial blood flow at Stage IV according to Fontaine received treatment by a standardised therapeutic scheme. None of the cases was suitable for reconstruction by vascular surgery. Infusion treatment, using Infukoll M 40 and Actovegin, was to be checked for its capability of providing sufficient improvement in blood flow and thus eliminating the need for imminent high-level amputation. Evaluation was undertaken on the basis of clinical and laboratory-chemical parameters. The rate of above-knee amputation was reduced by 14 per cent. Hence, the above therapeutic concept has proved to be suitable for treatment of Stage IV chronic arterial occlusion.